Research Highlights: Pharmacokinetic and dynamic genetic risk factors for QT prolongation with iloperidone therapy

Author： Stevenson James M Bishop Jeffrey R

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.14, Iss.12, 2013-09, pp. : 1377-1381

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

QT prolongation risk applies to most antidepressants

Reactions Weekly, Vol. 1, Iss. 1433, 2013-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Statistical Characterization of QT Prolongation

By Schall Robert

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 3, 2010-05 ,pp. : 543-562

Taylor & Francis Ltd

Access to resources Recommend Favorite

QT Interval Prolongation: And the Beat Goes on

Mini Reviews in Medicinal Chemistry, Vol. 5, Iss. 12, 2005-12 ,pp. : 1083-1091

Bentham Science Publishers

Access to resources Recommend Favorite

Intrauterine Growth Retardation is a Risk Factor for Cisapride-Induced QT Prolongation in Preterm Infants

By Corvaglia Luigi Faldella Giacomo Rotatori Raffaella Lanari Marcello Capretti Maria Salvioli Gian

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 5, 2004-09 ,pp. : 371-375

Springer Publishing Company

Access to resources Recommend Favorite

Commentary (Research Highlights: The Genetic Basis of “Running for Longevity”)

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 7, 2012-11 ,pp. : 801-802

Bentham Science Publishers

Access to resources Recommend Favorite